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ight Less Be More Than Enough?*
nne B. Curtis, MD, FACC
ampa, Florida
ince implantable cardioverter-defibrillators (ICDs) were
rst introduced in the early 1980s, defibrillation threshold
esting (DFT) at the time of implantation has been consid-
red mandatory because the results have been used to
redict the likelihood that these devices would successfully
erminate sustained ventricular tachyarrhythmias when they
ccurred clinically. From the initial days of epicardial patch
lacements through the early generations of transvenous
evices with monophasic shocks, failure to defibrillate, even
ith high-output shocks, was not uncommon. In addition
o intraoperative testing, the performance of DFT testing 1
r 2 days after implantation but before hospital discharge
ecame routine practice. The data acquired occasionally led
o the need for system revision. With the advent of biphasic
hocks in ICDs, mean defibrillation thresholds were lower,
nd it became much less common for system revision to be
ecessary. With the ability to reverse polarity, adjust the tilt
f the defibrillation waveform, or change the vector for
efibrillation, the need for the addition of a subcutaneous
atch or electrode array to the system is very rare in clinical
ractice today.
See page 551
The established reliability of current ICD systems has led
ost electrophysiologists to abandon the practice of routine
FT testing before hospital discharge. Even annual DFT
esting, once a common clinical practice, is performed
nfrequently today. In fact, DFT testing after implantation
s usually reserved now for specific situations, such as a
oncern about lead status or a change in drug therapy (e.g.,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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onsultant for and has received honoraria from St. Jude Medical.he addition of amiodarone) in the setting of a previously
arginal DFT.
Although practice patterns in the surveillance of patients
ith ICDs have evolved remarkably, there has been little
hange to date in the approach to the patient at the time of
mplantation. Defibrillation is a probabilistic phenomenon
n which the higher the shock strength, the higher the
ikelihood of successful defibrillation. The most common
pproach in clinical practice to approximating the DFT is to
nduce ventricular fibrillation at least twice and defibrillate
he patient with an energy setting at least 10 J less than
he maximum output of the ICD. Given the shape of the
efibrillation curve, this method should ensure an ade-
uate safety margin in the overwhelming majority of
atients, although it does not technically determine the
ctual DFT (1). The rare need for system revision and the
roven reliability of ICDs in terminating spontaneous,
ustained ventricular tachyarrhythmias have called into
uestion whether DFT testing at the time of implantation is
till required. Yet, physicians have been reluctant to aban-
on it, despite mounting evidence that it may no longer be
ecessary (2–6).
In this context we have new data acquired from patients
nrolled in the parent SCD-HeFT (Sudden Cardiac Death
n Heart Failure Trial) (7). As reported previously, SCD-
eFT was a primary prevention ICD trial that established
he superiority of single-chamber ICDs compared with
miodarone or placebo in improving survival in patients
ith symptomatic heart failure and left ventricular ejection
ractions 35% (8). In a SCD-HeFT substudy by Blatt et
l. (7), reported in this issue of the Journal, baseline DFT
ata were available for 717 patients implanted with ICDs.
he DFT protocol in the study was straightforward: ven-
ricular fibrillation was induced and 20-J shocks were
elivered. If defibrillation was achieved, ventricular fibrilla-
ion was reinduced and the effects of a 10-J shock were then
etermined. If 20 J failed the first time, 30 J was delivered
uring the second induction. Regardless of the outcome of
FT testing, all patients were programmed with the first
hock set at 10 J above the DFT (unless the DFT was 30 J,
n which case 30 J was programmed), with the maximum
utput for subsequent shocks and reverse polarity for the last
shocks. Defibrillation was achieved in all patients with the
se of shock strengths 30 J. In addition, 97.8% of the
atients had a DFT 20 J. The main findings of the study
ere that there was no difference in survival between
atients who had a DFT 10 J and those who had a DFT
10 J. First-shock efficacy for spontaneous events was
3.0%, with no significant difference according to baseline
FT. Of the 31 patients who had failed first shocks in
ollow-up, all survived the event, with 3 of the patients
ubsequently dying in the hospital from progressive heart
ailure. In most of these patients who survived a failed first
hock, the arrhythmia terminated spontaneously or subse-
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Editorial Comment August 12, 2008:557–8Of the 16 patients with a DFT between 21 and 30 J, only
 patients had an appropriate shock in follow-up, all of
hich were successful. Granted, this is a small number of
atients and events. However, there were over 700 patients
n this substudy, with a median follow-up of 45.5 months.
he 2.2% risk of an elevated DFT is comparable to what has
een seen in other studies. With that low level of risk for a
igh DFT, and a markedly lower risk of an adverse outcome
n follow-up, a much larger study with a prolonged
ollow-up would need to be done to detect a difference in
utcome, if indeed one exists. Whether such a slight
ifference in outcome would be clinically meaningful is also
uestionable.
It should be noted that defibrillation using shock energies
p to 30 J was successful in all patients in this substudy. It
s thus unknown what kind of outcome might be expected
n patients who failed defibrillation with the maximum
utput of an ICD at the time of implantation. However, it
s clear that in patients similar to those tested in SCD-
eFT, that finding would be exceedingly rare.
It is important to stress that the results of this study can
e applied only to similar patients who are receiving
ingle-chamber ICDs for primary prevention and are receiv-
ng standard-of-care background medical therapy for heart
ailure. The results should not be extrapolated to patients
eceiving cardiac resynchronization therapy, who often have
ore advanced disease. Whether the results could be
pplied to patients receiving dual-chamber ICDs is debat-
ble because the reason for the atrial lead may be a history
f atrial arrhythmias or a rare need for pacing that may not
ave an impact on defibrillation. The results should also not
e applied to patients who are receiving ICDs for secondary
revention, in whom life-threatening ventricular arrhyth-
ias have already occurred.
A recent decision analysis and Markov model found that
-year survival was nearly identical with or without DFT
esting (9). Only if the annual risk of a lethal arrhythmia was
t least 5% was there a slight advantage to DFT testing, but
he incremental benefit was minimal. Another factor that
ust be considered in recommendations regarding DFT
esting is the risk associated with this practice. Birnie et al.
10) recently reviewed the experience in Canada over a
-year period and found that among 19,067 patients with
CD implants, 3 deaths, 5 strokes, and 27 episodes of
rolonged resuscitation, some of which were associated with
erious clinical sequelae, were directly attributable to DFT
esting.
The current study is not the first to challenge the
onventional wisdom of routine DFT testing (2– 6). Viskin
nd Rosso (5) recently enumerated elegantly a myriad of
easons for avoiding DFT testing, including the lack of
orrelation between induced and spontaneous ventricular
brillation; the fact that many patients will never have
pontaneous ventricular fibrillation in follow-up; the reality
hat successful DFT testing at implant is so likely that little cnformation is gained as a result of the procedure in most
atients; the observation that spontaneous arrhythmias are
ften ventricular tachycardia, which is easier to cardiovert;
nd the fact that DFT testing is not without risk, among
thers.
These observations coupled with the results of the present
tudy indicate that routine DFT testing in stable patients
eceiving nonresynchronization ICDs for primary preven-
ion is of little clinical value. Driven by these results, it
ould be reasonable to consider whether practice guidelines
hould be revised to reflect these findings, with 2 important
aveats. First, a mounting consensus that routine DFT
esting may be safely abandoned in selected patients does
ot mean that it should be discontinued in all patients. We
o not have information on patients receiving cardiac
esynchronization devices and other specific situations as
entioned previously to make recommendations at this
ime. However, proof-of-concept has now been established
hat routine DFT testing is unlikely to provide sufficient
nformation that impacts ICD programming in the over-
helming majority of patients, and it carries some slight
isk. Collectively, these data justify a prospective trial
andomizing patients receiving ICDs for any indication to
FT testing versus no DFT testing, because less testing just
ight be more than enough.
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